Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Executive Summary

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

Advertisement

Related Content

NASH News & Notes From The European Liver Meeting
Novartis Dives Into Inflammasome Pool With IFM Tre Purchase
Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
In NASH Race, Bad News For Conatus, Good News For Genfit In PBC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel